Dalip Sethi, PhD profile page

As an innovative and transformational scientific leader, Dalip Sethi, PhD, MBA, MSc, currently serves as the commercial leader, Cell Therapy Technologies, North America. He holds a doctorate and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. In his post-doctoral research, Dalip focused on the development of cancer gene-specific RNA and DNA analogs targeted against cancer genes in the signal transduction pathway for use as cancer diagnostics and therapeutics. Throughout his career in the industry, Dalip has been engaged in developing technologies and methods for use in cell therapy applications. Dalip has authored multiple scientific publications and is a co-inventor on several patents and patent applications. He recently co-authored publications on modular automated systems for CD3+ T-cell manufacturing and monoculture of cord-blood derived CD34+ using an automated, membrane-based dynamic perfusion system. The articles highlighted the benefits of modular automation in cell therapy manufacturing. Dalip is also an ISCT member and participates in committees focused on cold chain, particulates and process analytical technologies.